Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Basic and translational research in neonatal pharmacology

Journal of Perinatology volume 26, pages S8–S12 (2006)Cite this article

Abstract

Pharmacologic study is needed in the extremely immature newborns who currently survive. Study is needed of both the drug treatment previously established in more mature neonates and of novel drug therapy. Carefully controlled studies are needed to identify accurately both beneficial and harmful drug therapy and the mechanisms of that toxicity. Careful pharmacologic study of drug disposition and its mechanisms might lead to dosing paradigms or patient selection that minimize toxicity and maximize efficacy. In vivo, translational models of neonatal diseases are limited, but can be used to identify novel treatments and study mechanisms of established, successful therapy. Findings from such studies can generate hypotheses for study in humans leading to a continuing scientific interchange from bedside to bench to bedside. Similarly, clinical observations can generate hypotheses for study in translational models where more invasive analyses are possible. Specific areas of drug treatment should focus on neonatal disorders with long-term, adverse outcomes, such as chronic lung disease, that is amenable to translational study with animal models. National data show a progressive decrease in the clinician-scientist pool entering biomedical research. The future of neonatal pharmacology studies requires an increase in training programs for the physician-scientist whose clinical education in neonatology can be complemented by rigorous basic-science training. Success as a clinician-scientist will require collaboration with full-time basic scientists who can continue studies during periods of clinical work and provide critical study methodology to the overall study design. Such a work environment must be supported by academic institutions and may require more flexibility in the promotion and tenure schedule and process, such as the nature of what it rewards. To complement this, the NIH could modify its grant reporting process to identify co-investigators in studies who may provide unique input to the study concepts and design, such as clinical correlations or clinical investigations.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Vohr BR, Wright LL, Dusick AM, Mele L, Verter J, Steichen JJ et al. Neurodevelopmental and functional outcomes of extremely low birth weight infants in the National Institute of Child Health and Human Development Neonatal Research Network, 1993–1994. Pediatrics 2000; 105: 1216.

    Article  CAS  Google Scholar 

  2. Albertine KH, Jones GP, Starcher BC, Bohnsack JF, Davis PL, Cho SC et al. Chronic lung injury in preterm lambs. Disordered respiratory tract development. Am J Respir Crit Care Med 1999; 159: 945.

    Article  CAS  Google Scholar 

  3. Ward RM, Beachy JC . Neonatal complications following preterm birth. Br J Obstet Gynec 2003; 110 (Suppl 20): 8.

    Article  Google Scholar 

  4. O'Shea TM, Klinepeter KL, Goldstein DJ, Jackson BW, Dillard RG . Survival and developmental disability in infants with birth weights of 501 to 800 grams, born between 1979 and 1994. Pediatrics 1997; 100: 982.

    Article  CAS  Google Scholar 

  5. O'Shea TM, Preisser JS, Klinepeter KL, Dillard RG . Trends in mortality and cerebral palsy in a geographically based cohort of very low birth weight neonates born between 1982 to 1994. Pediatrics 1998; 101: 642.

    Article  CAS  Google Scholar 

  6. St John EB, Carlo WA . Respiratory distress syndrome in VLBW infants: changes in management and outcomes observed by the NICHD Neonatal Research Network. Semin Perinatol 2003; 27: 288.

    Article  Google Scholar 

  7. Schreiber MD, Gin-Mestan K, Marks JD, Huo D, Lee G, Srisuparp P . Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med 2003; 349: 2099.

    Article  CAS  Google Scholar 

  8. Horbar JD, Stillman AL . Vermont Oxford Network Annual Database Summary for 2000. Vermont Oxford Network: Burlington; 2002.

    Google Scholar 

  9. Ward RM . Pharmacologic principles and practicalities. In: Taeusch HW, Ballard RA (eds). Avery's Diseases of the Newborn. W.B. Saunders: Philadelphia; 1998, pp 404–412.

    Google Scholar 

  10. Ward RM . Adverse effects of drugs in the newborn. In: Rudolph CD RA, Hostetter MK, Lister G, Siegel NJ (eds). Rudolph's Pediatrics. McGraw-Hill: New York; 2003, pp 146–148.

    Google Scholar 

  11. Burns LE, Hodgeman JE, Cass AB . Fatal and circulatory collapse in premature infants receiving chloramphenicol. N Engl J Med 1959; 261: 1318.

    Article  CAS  Google Scholar 

  12. Ward RM, Daniel CH, Kendig JW . Oliguria and tolazoline pharmacokinetics in the newborn. Pediatrics 1986; 77: 307.

    CAS  PubMed  Google Scholar 

  13. Lacroix D, Sonnier M, Moncion A, Cheron G, Cresteil T . Expression of CYP3A in the human liver – evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 1997; 247: 625.

    Article  CAS  Google Scholar 

  14. Mammel MC, Johnson DE, Green TP, Thompason TR . Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet 1983; 1: 1356.

    Article  CAS  Google Scholar 

  15. Avery GB, Fletcher AB, Kaplan M, Brudno DS . Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia. Pediatrics 1985; 75: 106.

    CAS  Google Scholar 

  16. Lugo RA, Nahata MC, Menke JA, McClead Jr RE . Pharmacokinetics of dexamethasone in premature neonates. Eur J Clin Pharmacol 1996; 49: 477.

    Article  CAS  Google Scholar 

  17. Charles B, Schild P, Steer P, Cartwright D, Donovan T . Pharmacokinetics of dexamethasone following single-dose intravenous administration to extremely low birth weight infants. Dev Pharmacol Ther 1993; 20: 205.

    Article  CAS  Google Scholar 

  18. Stark AR, Carlo WA, Tyson JE, Papile LA, Wright LL, Shankaran S et al. Adverse effects of early dexamethasone in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 2001; 344: 95.

    Article  CAS  Google Scholar 

  19. Shinwell ES, Karplus M, Reich D, Weintraub Z, Blazer S, Bader D et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed 2000; 83: F177.

    Article  CAS  Google Scholar 

  20. Yeh TF, Lin YJ, Lin HC, Huang CC, Hsieh WS, Lin CH et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 2004; 350: 1304.

    Article  CAS  Google Scholar 

  21. Romagnoli C, Zecca E, Luciano R, Torrioli G, Tortorolo G . A three year follow up of preterm infants after moderately early treatment with dexamethasone. Arch Dis Child Fetal Neonatal Ed 2002; 87: F55.

    Article  CAS  Google Scholar 

  22. Canlon B, Erichsen S, Nemlander E, Chen M, Hossain A, Celsi G et al. Alterations in the intrauterine environment by glucocorticoids modifies the developmental programme of the auditory system. Eur J Neurosci 2003; 17: 2035.

    Article  Google Scholar 

  23. Ikeda T, Mishima K, Yoshikawa T, Iwasaki K, Fujiwara M, Xia YX et al. Dexamethasone prevents long-lasting learning impairment following neonatal hypoxic-ischemic brain insult in rats. Behav Brain Res 2002; 136: 161.

    Article  CAS  Google Scholar 

  24. Young TE, Kruyer LS, Marshall DD, Bose CL . Population-based study of chronic lung disease in very low birth weight infants in North Carolina in 1994 with comparisons with 1984. The North Carolina Neonatologists Association. Pediatrics 1999; 104: e17.

    Article  CAS  Google Scholar 

  25. Van Marter LJ, Allred EN, Pagano M, Sanocka U, Parad R, Moore M et al. Do clinical markers of barotrauma and oxygen toxicity explain interhospital variation in rates of chronic lung disease? The Neonatology Committee for the Developmental Network. Pediatrics 2000; 105: 1194.

    Article  CAS  Google Scholar 

  26. Bland RD, Albertine KH, Carlton DP, Kullama L, Davis P, Cho SC et al. Chronic lung injury in preterm lambs: abnormalities of the pulmonary circulation and lung fluid balance. Pediatr Res 2000; 48: 64.

    Article  CAS  Google Scholar 

  27. Bland RD, Ling CY, Albertine KH, Carlton DP, MacRitchie AJ, Day RW et al. Pulmonary vascular dysfunction in preterm lambs with chronic lung disease. Am J Physiol Lung Cell Mol Physiol 2003; 285: L76.

    Article  CAS  Google Scholar 

  28. Thomson MA, Yoder BA, Winter VT, Martin H, Catland D, Siler-Khodr TM et al. Treatment of immature baboons for 28 days with early nasal continuous positive airway pressure. Am J Respir Crit Care Med 2004; 169: 1054.

    Article  Google Scholar 

  29. Darlow BA, Graham PJ . Vitamin A supplementation for preventing morbidity and mortality in very low birthweight infants. Cochrane Database Syst Rev 2002 CD000501.

  30. OBrien EA, Zhao L, Dahl MJ, McKnight RA, Reyburn B, Callaway CW et al. NCPAP and vitamin A treatment increase pulmonary TGF-b and SMAD mRNA levels in premature sheep. Pediatr Res 2004; 55: 507A.

    Article  Google Scholar 

  31. OBrien EA, Zhao L, McKnight RA, Dahl MJ, Callaway CW, Reyburn B et al. NCPAP and vitamin A treatment increase pulmonary c-myc and c-jun mRNA levels in the premature sheep. Pediatr Res 2004; 55: 507A.

    Article  Google Scholar 

  32. Grinder D, Ward RM . Public meeting on the FDA's proposed regulation requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients. J Pediatr Pharm Pract 1997; 2: 331.

    Google Scholar 

  33. Ward RM . Children, drugs, and the Food and Drug Administration: studies of pediatric drugs are beginning to catch up. Pediatr Ann 2001; 30: 189.

    Article  CAS  Google Scholar 

  34. Leeder JS, Kearns GL . Pharmacogenetics in pediatrics. Implications for practice. Pediatr Clin North Am 1997; 44: 55.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported in part by Grant NICHD PPRU 1 U10 HD045986-01 to RM Ward Grant R01 HD41075 to RH Lane; and Children's Health Research Center Grants R01 HL62875, P50 HL5640, and T35 HL07744 to KH Albertine

Author information

Authors and Affiliations

  1. University of Utah Department of Pediatrics, Pediatric Pharmacology Program, Salt Lake City, UT, USA

    R M Ward

  2. Division of Neonatology, University of Utah Department of Pediatrics, Salt Lake City, UT, USA

    R M Ward, R H Lane & K H Albertine

Authors
  1. R M Ward
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R H Lane
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K H Albertine
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R M Ward.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ward, R., Lane, R. & Albertine, K. Basic and translational research in neonatal pharmacology. J Perinatol 26 (Suppl 2), S8–S12 (2006). https://doi.org/10.1038/sj.jp.7211423

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jp.7211423

Keywords

This article is cited by

Search

Advanced search

Quick links